Celgene, Sutro sign antibody deal; later expanded
Sutro Biopharma Inc. (large molecule therapeutics) will design and develop optimized antibody drug conjugates (ADCs) and bispecific antibodies (BSAs) for two of Celgene Corp.’s undisclosed targets.
- Synthesis Technologies, Production Processes
- Includes Contract
- Includes Equity
- Includes M&A Option
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.